Filing Flows › Rigel Pharmaceuticals (RIGL) › Guidance & outlook
Rigel Pharmaceuticals (RIGL) guidance and outlook
Rigel Pharmaceuticals (RIGL) raised some and lowered other parts of its guidance on Nov 5, 2026: Revenue $290M–$295M for FY2026. Rigel Pharmaceuticals' 10-Q filed Nov 5, 2026 makes 28 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $255M–$260M | lowered |
| Revenue | FY2026 | $290M–$295M | raised |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- Under the license agreement, we will have the sole rights and will be primarily responsible for the development and commercialization of the licensed products worldwide, subject to certain transition activities to be performed by the Licensors.
- On November 4, 2026, we announced that we will present updated data from our ongoing Phase 1b study evaluating R289 in patients with R/R lower-risk MDS in an oral presentation at the upcoming 68th ASH Annual Meeting and Exposition taking place December 12-15, 2026, in New Orleans, Louisiana, and virtually.
- We continue to advance our Phase 1b study and expect to complete the enrollment and select the recommended Phase 2 dose for future development by the end of 2026.
- In our sponsored arm, TarGet-D, adolescents and young adult patients (ages 12 to 39 years old) with newly-diagnosed IDH1 -mutation positive HGG will receive maintenance therapy with olutasidenib in combination with temozolomide for the first year after radiotherapy, followed by olutasidenib monotherapy for the second year.
- Under the collaboration, we will provide CONNECT with funding up to $3.0 million and study material over the four-year collaboration.
- Following termination, the rights previously licensed to Lilly under the Lilly Agreement reverted to us in accordance with the terms of the Lilly Agreement, and we do not expect to receive any future milestone payments or royalties thereunder.
- In addition, a number of companies are pursuing the development of pharmaceuticals that target the same diseases and conditions that we are targeting.
- Our commercial effort focuses on growing awareness of REZLIDHIA within key institutions, and among targeted HCPs who manage patients with R/R AML with m IDH1 .
- It is estimated that over 229,000 adult patients in the US will be diagnosed with lung cancer in 2026.
- Based on published epidemiology and our assessment of the treatment landscape, we estimate that approximately 20,000 patients in the US with second line- or third-line ER+/HER2-, ESR1 -mutated advanced or metastatic breast cancer may be candidates for therapies targeting this patient population.
- We have filed applications for patent term extension for the Orange Book-listed patents, one of which, if granted, is expected to extend patent protection until May 2040.
- On November 4, 2026, we announced that we will
Rigel Pharmaceuticals' latest quarter
Rigel Pharmaceuticals, Q3 2026: revenue $80.9M (+16% year over year), operating margin 21.1%, net earnings $13.2M, operating cash flow $34.6M. The chart follows the revenue to costs, profit and cash.
Questions
Did Rigel Pharmaceuticals raise or lower its guidance?
Rigel Pharmaceuticals (RIGL) raised some and lowered other parts of its guidance on Nov 5, 2026: Revenue $290M–$295M for FY2026.
What does Rigel Pharmaceuticals expect?
Under the license agreement, we will have the sole rights and will be primarily responsible for the development and commercialization of the licensed products worldwide, subject to certain transition activities to be performed by the Licensors. On November 4, 2026, we announced that we will present updated data from our ongoing Phase 1b study evaluating R289 in patients with R/R lower-risk MDS in an oral presentation at the upcoming 68th ASH Annual Meeting and Exposition taking place December 12-15, 2026, in New Orleans, Louisiana, and virtually. We continue to advance our Phase 1b study and e
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.